Country: Canada
Language: English
Source: Health Canada
MEASLES VIRUS VACCINE LIVE ATTENUATED (EDMONSTON B STRAIN); MUMPS VIRUS VACCINE LIVE ATTENUATED (JERYL LYNN STRAIN); RUBELLA VIRUS VACCINE LIVE ATTENUATED (WISTAR RA27/3 STRAIN); VARICELLA-ZOSTER VIRUS VACCINE LIVE ATTENUATED (OKA/MERCK STRAIN)
MERCK CANADA INC
J07BD54
MEASLES, COMBINATIONS WITH MUMPS, RUBELLA AND VARICELLA, LIVE ATTENUATED
3.00Log10 TCID50; 4.30Log10 TCID50; 3.00Log10 TCID50; 3.99Log10 PFU
POWDER FOR SOLUTION
MEASLES VIRUS VACCINE LIVE ATTENUATED (EDMONSTON B STRAIN) 3.00Log10 TCID50; MUMPS VIRUS VACCINE LIVE ATTENUATED (JERYL LYNN STRAIN) 4.30Log10 TCID50; RUBELLA VIRUS VACCINE LIVE ATTENUATED (WISTAR RA27/3 STRAIN) 3.00Log10 TCID50; VARICELLA-ZOSTER VIRUS VACCINE LIVE ATTENUATED (OKA/MERCK STRAIN) 3.99Log10 PFU
SUBCUTANEOUS
0.5ML
Schedule D
VACCINES
Active ingredient group (AIG) number: 0453533002; AHFS:
APPROVED
2012-12-21
_ProQuad®_ _(Measles, Mumps, Rubella and Varicella Virus Vaccine Live)_ _ _ _Page 1 of 45 _ PRODUCT MONOGRAPH INCLUDING PATIENT MEDICATION INFORMATION PROQUAD® (Measles, Mumps, Rubella and Varicella Virus Vaccine Live) Lyophilized powder for injection (0.5 mL/dose after reconstitution) Active Immunizing Agent Against Measles, Mumps, Rubella and Varicella Merck Canada Inc. 16750 route Transcanadienne Kirkland QC Canada H9H 4M7 www.merck.ca Date of Initial Authorization: December 21, 2012 Date of Revision: October 13, 2022 Submission Control Number: 259191 _ProQuad_ _®_ _ (Measles, Mumps, Rubella and Varicella Virus Vaccine Live) _ _Page 2 of 45_ RECENT MAJOR LABEL CHANGES Not applicable. TABLE OF CONTENTS SECTIONS OR SUBSECTIONS THAT ARE NOT APPLICABLE AT THE TIME OF AUTHORIZATION ARE NOT LISTED . RECENT MAJOR LABEL CHANGES............................................................................................ 2 NOT APPLICABLE........................................................................................................................ 2 TABLE OF CONTENTS .............................................................................................................. 2 PART I: HEALTH PROFESSIONAL INFORMATION ..................................................................... 4 1 INDICATIONS .............................................................................................................. 4 2 CONTRAINDICATIONS ................................................................................................. 4 4 DOSAGE AND ADMINISTRATION................................................................................. 5 4.1 Dosing Considerations ....................................................................................... 5 4.2 Recommended Dose and Dosage Adjustment..................................................... 5 4.3 Reconstitution ................................................................................................... 5 4.4 Administration......................... Read the complete document